• First prescriptions for Khiron’s medical cannabis in Peru are filled as the Company surpasses 3,000 medical cannabis prescription milestone in Colombia
  • Khiron becomes the first Company to sell and fill medical cannabis prescriptions through private pharmacies in Peru
  • The Company began sales in Peru with full spectrum High CBD supplied by Khiron Colombia and distributed to patients under the previously announced agreement with Farmacia Universal S.A.C.
  • Farmacia Universal is an established pharmacy chain, with 10 locations in Lima
  • Quotas for Khiron’s high THC medical cannabis have also been approved by DIGEMID, Peru’s drug regulatory authority, with first prescriptions anticipated in Q4 2020
  • With a population of 32 million, Peru’s medical cannabis market is expected to be one of the largest in Latin America

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced that it has filled the first prescriptions of full spectrum, high CBD medical cannabis to patients in Peru . This comes following authorization from DIGEMID, Peru’s drug regulatory authority, and expands sales of Khiron’s medical cannabis to a second jurisdiction in Latin America following established sales in Colombia where over 3,000 prescriptions have been filled to date.

“After completing successfully all export, import and distribution requirements to bring our approved high CBD medical cannabis products into Peru , we are now very proud to begin sales and give patients greater access to medical cannabis therapies in order to improve significantly their quality of life,” comments Luis Marquez , Khiron Peru Country Manager.

In Peru, only registered pharmaceutical establishments that have received Good Storage Practices (GSP) certification and licenses to import and commercialize medical cannabis are authorized to participate in the wholesale import and commercialization of cannabis products. Khiron Peru is a GSP certified, registered pharmaceutical establishment, and Farmacia Universal has all required permits and licenses, including Good Manufacturing Practices (GMP) certification, to prepare magistral preparations with medical cannabis and distribute final products to patients through pharmacies under the previously announced agreement with Khiron.

“At Khiron we continue to execute on our stated strategy to deliver quality medical cannabis products to patients and to improve the quality of their lives. In a short period of time, and despite a global pandemic, we have filled over 3,000 medical cannabis prescriptions in Colombia , and today we are pleased to expand that reach, filling our first patient prescriptions in Peru , an important market of 32 million people,” comments Alvaro Torres , Khiron CEO and director.

Additionally, quotas for Khiron’s high THC medical cannabis product in Peru have also been approved by DIGEMID, with first patient prescriptions anticipated to be filled in Q4 2020.

Farmacia Universal S.A.C. is a well-known Peruvian pharmacy chain. The company operates ten locations in Lima and is a leader in the pharmaceutical preparations sector in Peru . In addition to selling pharmaceutical, surgical and orthopedic products, among others, the company differentiates its brand with premium service to customers and patients.

About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America , and operational activity in Europe and North America . Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico , Uruguay , UK, Spain and also in Germany , where it is positioned to begin sales of medical cannabis.

Leveraging its first-mover advantage and patient-oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia , with Kuida now marketed in multiple jurisdictions in Latin America , the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife .

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/khiron-becomes-first-company-to-sell-medical-cannabis-in-peru-and-surpasses-3-000-prescriptions-in-colombia-301137757.html

SOURCE Khiron Life Sciences Corp.

News Provided by Canada Newswire via QuoteMedia

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less